Altimmune (ALT) Free Cash Flow (2010 - 2026)
Altimmune (ALT) posted quarterly Free Cash Flow of -$21.0 million for Q1 2026, down 24.48% year-over-year from -$27.8 million in Q1 2025, and down 7.78% quarter-over-quarter from -$19.4 million in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Free Cash Flow (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Free Cash Flow for 17 consecutive years, with -$21.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 24.48% year-over-year to -$21.0 million; the TTM figure through Mar 2026 stood at -$71.7 million (up 10.8% YoY), while the FY2025 annual figure was -$67.5 million, up 15.41% from the prior year.
- Free Cash Flow declined to -$21.0 million in Q1 2026 per ALT's latest filing, from -$19.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$11.9 million in Q3 2025 and bottomed at -$27.1 million in Q3 2024.
- Historically, Free Cash Flow has averaged -$18.1 million across 5 years, with a median of -$18.1 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow sank 43.76% — and 2025, when it soared 56.13%.
- Altimmune's Free Cash Flow stood at -$17.3 million in 2022, then rose by 4.68% to -$16.5 million in 2023, then decreased by 10.48% to -$18.3 million in 2024, then decreased by 6.48% to -$19.4 million in 2025, then declined by 7.78% to -$21.0 million in 2026.
- Business Quant data shows ALT's Free Cash Flow at -$21.0 million in Q1 2026, -$19.4 million in Q4 2025, and -$11.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | -24.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.25 Mn |
| Mar 31, 2026 | -20.96 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Mar 31, 2024 | -16.36 Mn |
| Dec 31, 2023 | -16.53 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -19.38 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -17.34 Mn |
| Sep 30, 2022 | -15.11 Mn |
| Jun 30, 2022 | -16.72 Mn |
| Mar 31, 2022 | -13.54 Mn |
| Dec 31, 2021 | -22.11 Mn |
| Sep 30, 2021 | -17.85 Mn |